These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11583481)

  • 1. Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients.
    Schwartz JI; Agrawal NG; Wong PH; Bachmann KA; Porras AG; Miller JL; Ebel DL; Sack MR; Holmes GB; Redfern JS; Gertz BJ
    J Clin Pharmacol; 2001 Oct; 41(10):1120-30. PubMed ID: 11583481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Examination of the effect of increasing doses of etoricoxib on oral methotrexate pharmacokinetics in patients with rheumatoid arthritis.
    Schwartz JI; Agrawal NG; Wong PH; Miller J; Bachmann K; Marbury T; Hoelscher D; Cavanaugh PF; Gottesdiener K
    J Clin Pharmacol; 2009 Oct; 49(10):1202-9. PubMed ID: 19783714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients.
    Hartmann SN; Rordorf CM; Milosavljev S; Branson JM; Chales GH; Juvin RR; Lafforgue P; Le Parc JM; Tavernier CG; Meyer OC
    Ann Pharmacother; 2004 Oct; 38(10):1582-7. PubMed ID: 15340127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers.
    Schwartz JI; De Smet M; Larson PJ; Verbesselt R; Ebel DL; Lins R; Lens S; Porras AG; Gertz BJ
    J Clin Pharmacol; 2001 Jan; 41(1):107-12. PubMed ID: 11144988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group.
    Schnitzer TJ; Truitt K; Fleischmann R; Dalgin P; Block J; Zeng Q; Bolognese J; Seidenberg B; Ehrich EW
    Clin Ther; 1999 Oct; 21(10):1688-702. PubMed ID: 10566565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of rofecoxib on prednisolone and prednisone pharmacokinetics in healthy subjects.
    Schwartz JI; Mukhopadhyay S; Porras AG; Viswanathan-Aiyer KJ; Adcock S; Ebel DL; Gertz BJ
    J Clin Pharmacol; 2003 Feb; 43(2):187-92. PubMed ID: 12616672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of rofecoxib in children with sickle cell hemoglobinopathy.
    Prescilla RP; Frattarelli DA; Haritos D; Aranda JV; Edwards DJ
    J Pediatr Hematol Oncol; 2004 Oct; 26(10):661-4. PubMed ID: 15454838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs.
    Halpin RA; Geer LA; Zhang KE; Marks TM; Dean DC; Jones AN; Melillo D; Doss G; Vyas KP
    Drug Metab Dispos; 2000 Oct; 28(10):1244-54. PubMed ID: 10997947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid and plasma pharmacokinetics of the cyclooxygenase 2 inhibitor rofecoxib in humans: single and multiple oral drug administration.
    Buvanendran A; Kroin JS; Tuman KJ; Lubenow TR; Elmofty D; Luk P
    Anesth Analg; 2005 May; 100(5):1320-1324. PubMed ID: 15845677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study.
    Hawkey CJ; Laine L; Simon T; Quan H; Shingo S; Evans J;
    Gut; 2003 Jun; 52(6):820-6. PubMed ID: 12740337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis.
    Geusens PP; Truitt K; Sfikakis P; Zhao PL; DeTora L; Shingo S; Lau CS; Kalla A; Tate G
    Scand J Rheumatol; 2002; 31(4):230-8. PubMed ID: 12369656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.
    Matheson AJ; Figgitt DP
    Drugs; 2001; 61(6):833-65. PubMed ID: 11398914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake.
    Huledal G; Jonzon B; Malmenäs M; Hedman A; Andersson LI; Odlind B; Brater DC
    Clin Pharmacol Ther; 2005 May; 77(5):437-50. PubMed ID: 15900289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis.
    Vakily M; Amer F; Kukulka MJ; Andhivarothai N
    J Clin Pharmacol; 2005 Oct; 45(10):1179-86. PubMed ID: 16172183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of renal insufficiency and hemodialysis on the pharmacokinetics of rofecoxib.
    Gottesdiener K; Agrawal N; Porras A; Wong P; Rogers JD; Gertz BJ; Redfern JS; Marbury T
    Am J Ther; 2003; 10(4):252-8. PubMed ID: 12845388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analgesic efficacy of the cyclooxygenase-inhibiting nitric oxide donor AZD3582 in postoperative dental pain: Comparison with naproxen and rofecoxib in two randomized, double-blind, placebo-controlled studies.
    Michael Hill C; Sindet-Pederson S; Seymour RA; Hawkesford JE; Coulthard P; Lamey PJ; Gerry Cowan C; Wickens M; Jeppsson L; Dean AD; Svensson O
    Clin Ther; 2006 Sep; 28(9):1279-95. PubMed ID: 17062301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fostamatinib, a Syk-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis.
    Baluom M; Samara E; Grossbard EB; Lau DT
    J Clin Pharmacol; 2011 Sep; 51(9):1310-8. PubMed ID: 21209239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of perioperative administration of a selective cyclooxygenase 2 inhibitor on pain management and recovery of function after knee replacement: a randomized controlled trial.
    Buvanendran A; Kroin JS; Tuman KJ; Lubenow TR; Elmofty D; Moric M; Rosenberg AG
    JAMA; 2003 Nov; 290(18):2411-8. PubMed ID: 14612477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
    Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of the dose-dependent inhibition of CYP1A2 by rofecoxib using theophylline as a CYP1A2 probe.
    Bachmann K; White D; Jauregui L; Schwartz JI; Agrawal NG; Mazenko R; Larson PJ; Porras AG
    J Clin Pharmacol; 2003 Oct; 43(10):1082-90. PubMed ID: 14517190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.